WE STAY ON TOP OF INDUSTRY TRENDS
In 1916, Jay McLean, then a second-year medicine student, was doing research in which he isolated a phosphatide (fat soluble compound) from canine liver cells with apparent in vitroanticoagulant properties that caused excess bleeding in experimental animals. However, McLean had to leave college in 1917 because of lack of money. Today, one of the oldest drugs still in widespread use: heparin, along with vitamin K antagonists, have been the main anticoagulant drugs for more than 70 years, as it has been used since the 1930s. Although it was first discovered almost a century ago, many years would have to pass until it could be mass produced and used as an anti-coagulant.READ MORE
ALBANY, New York, August 18, 2016 /PRNewswire/ --
According to TMR, The global heparin market stood at US$8.2 bn in 2014. Rising at a CAGR of 6.3% from 2015 to 2023, the market is expected to reach US$14.3 bn by the end of 2023. The demand for low molecular weight heparin (LMWH) was the highest in the market in 2014. By 2023, the LMWH segment is expected to reach US$12.3 bn. Regionally, North America emerged as the dominant segment in 2014. The rising incidence of DVT and pulmonary embolism (PE) will enable the North America market to exhibit a CAGR of 5.9% between 2014 and 2023.
A moderate degree of rivalry exists among the key players in the global heparin market. However, these companies exhibit a clear dominance in individual segments, finds Transparency Market Research (TMR). In a highly fragmented global heparin market, the top three vendors, Sanofi S.A., Leo Pharma A/S, and Pfizer, Inc. held a share of over 39.6% in 2014. Due to its long-standing market presence, Sanofi emerged as the market leader in the same year.READ MORE
According to the latest research report released by Technavio, the global heparin market will likely reach over USD 5 billion by 2020.
This report titled "Global Heparin Market 2016-2020", provides an in-depth analysis of the market in terms of revenue and emerging trends. To calculate the market size, the report considers revenue generated from the sales of branded and generics used to treat disorders.
The use of heparin may lead to bleeding, which could be managed using protamine, an antidote for heparin-related bleeding. However, protamine was found to have side effects such as hypertension and decreased heart rate. Hence, extensive research was done to develop agents with lesser side-effects. This led to the development of universal heparin reversal agents (UHRAs) by researchers of The University of British Columbia, Canada. These are synthetic dendritic polymers, which neutralizes anticoagulant effects, said Barath Palada, one of Technavios lead industry analysts for healthcare and life sciences.READ MORE